Company intelligence / Profile preview
Guangzhou Ruifeng Biotechnology
Guangzhou, Guangdong Sheng, Chinaruifengbio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Guangzhou Ruifeng Biotechnology is developing advanced gene therapies using CRISPR/Cas9 and AAV vectors. Its lead program RM-004 is in Phase 1 clinical trials for alpha-thalassemia. The company has a pipeline spanning preclinical to early clinical stages targeting rare blood disorders and other genetic conditions.
- Therapeutic areas
- Hematology
- Modalities
- Gene therapyCRISPR/Cas9-based therapyAAV-based gene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Guangzhou Ruifeng Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Ruifeng Biotechnology.